Products & ReviewLife Sciences

Dabrafenib

MEK/ERK pathway inhibitor; Inhibits B­RAF V600E

STEMCELL Technologies Inc.

The supplier does not provide quotations for this product through SelectScience. You can search for similar products in our  Product Directory.

Ease of Use
After Sales Service
Value for Money
Write your own review

Dabrafenib is a reversible, selective, and ATP-competitive inhibitor of B-RAF with higher potency towards V600E mutant B-RAF over wild-type B-RAF or C-RAF, with IC₅₀ values of 0.8, 3.2 and 5 nM, respectively (Laquerre et al.; Menzies et al.).

CANCER RESEARCH

  • Decreases ERK phosphorylation and inhibits cell proliferation in cells expressing the B-RAF mutation V600E. Prevents tumor growth in mouse xenograft models of B-RAF(V600E) human melanoma and colon cancer (Rheault et al.).

DISEASE MODELING

  • Alleviates acetaminophen-induced liver injury through distinct nanomolar inhibition of receptor-interacting protein (RIP3) in mice (Li et al.).

Product Overview

Links